Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $1.2 million.

  • Seres Therapeutics' Gains from Investment Securities fell 9378.41% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 9378.41%. This contributed to the annual value of $17.7 million for FY2024, which is 1937.61% up from last year.
  • According to the latest figures from Q3 2025, Seres Therapeutics' Gains from Investment Securities is $1.2 million, which was down 9378.41% from $1.2 million recorded in Q2 2025.
  • Over the past 5 years, Seres Therapeutics' Gains from Investment Securities peaked at $87.0 million during Q4 2022, and registered a low of -$416000.0 during Q1 2024.
  • Over the past 5 years, Seres Therapeutics' median Gains from Investment Securities value was $13.3 million (recorded in 2021), while the average stood at $14.8 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first soared by 104483.76% in 2022, then crashed by 10247.23% in 2024.
  • Over the past 5 years, Seres Therapeutics' Gains from Investment Securities (Quarter) stood at $7.6 million in 2021, then surged by 1044.84% to $87.0 million in 2022, then crashed by 97.92% to $1.8 million in 2023, then soared by 956.0% to $19.1 million in 2024, then tumbled by 93.78% to $1.2 million in 2025.
  • Its last three reported values are $1.2 million in Q3 2025, $1.2 million for Q2 2025, and $1.2 million during Q1 2025.